These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39382564)

  • 1. Short-term efficiency of plasma exchange in combination with immunosuppressants and/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta-analysis.
    Yang Y; Yang YT; Huo RX; Meng DL; Huang XX; Lin JY
    Ann Med; 2024 Dec; 56(1):2411605. PubMed ID: 39382564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes With and Without Plasma Exchange in the Treatment of Rapidly Progressive Interstitial Lung Disease Associated With Idiopathic Inflammatory Myopathy.
    Eggleston RH; Baqir M; Varghese C; Pennington KM; Bekele DI; Hartman TE; Ernste FC
    J Clin Rheumatol; 2023 Apr; 29(3):151-158. PubMed ID: 36729874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
    Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
    Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
    Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
    Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Initiation of Plasma Exchange Therapy for Anti-MDA5
    Sasaki N; Nakagome Y; Kojima A; Shimura K; Ishii A; Sugiyama M; Izumi Y; Hirano K; Kurabayashi T; Hosono Y; Yamada C; Sato S
    Intern Med; 2024 Jan; 63(2):213-219. PubMed ID: 37225493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum ferritin as a significant biomarker for patients with idiopathic inflammatory myopathy-associated interstitial lung disease: A systematic review and meta-analysis.
    He X; Ji J; Chen X; Luo Z; Fang S; Yan H; Guo L
    Semin Arthritis Rheum; 2024 Feb; 64():152350. PubMed ID: 38086199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
    Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
    Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis.
    Barba T; Fort R; Cottin V; Provencher S; Durieu I; Jardel S; Hot A; Reynaud Q; Lega JC
    Autoimmun Rev; 2019 Feb; 18(2):113-122. PubMed ID: 30572131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.
    Zhong L; Yu Z; Song H
    Clin Immunol; 2019 Jan; 198():11-18. PubMed ID: 30445156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases.
    Li S; Sun Y; Shao C; Huang H; Wang Q; Xu K; Zhang X; Liu P; Zeng X; Xu Z
    Rheumatology (Oxford); 2021 Mar; 60(3):1195-1204. PubMed ID: 32894294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis.
    Wang H; Lv J; He J; Wu W; Zhong Y; Cao S; Cai Y; Wang Q
    Autoimmun Rev; 2023 Aug; 22(8):103335. PubMed ID: 37164215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy.
    Weng CT; Huang TH; Wu CH; Sun YT
    Arthritis Res Ther; 2024 Aug; 26(1):152. PubMed ID: 39175076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
    Teel A; Lu J; Park J; Singh N; Basharat P
    Semin Arthritis Rheum; 2022 Dec; 57():152088. PubMed ID: 36116345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis.
    Nayebirad S; Mohamadi A; Yousefi-Koma H; Javadi M; Farahmand K; Atef-Yekta R; Tamartash Z; Jameie M; Mohammadzadegan AM; Kavosi H
    BMJ Open Respir Res; 2023 Nov; 10(1):. PubMed ID: 38030264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple values of
    Li Y; Zhou Y; Wang Q
    Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.
    Bay P; de Chambrun MP; Rothstein V; Mahevas M; De Prost N; Roux A; Zuber B; Biet DI; Hervier B; Tazi A; Mouthon L; Mekinian A; Deligny C; Borie R; Meurice JC; Meyer A; Priou P; Savale L; De Saint Martin L; Gallay L; Cottin V; Blanchard E; Brillet PY; Khafagy P; Benveniste O; Nunes H; Allenbach Y; Uzunhan Y
    J Autoimmun; 2022 Dec; 133():102941. PubMed ID: 36323067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.
    Bai Z; Shen G; Dong L
    Int J Rheum Dis; 2021 Jun; 24(6):815-827. PubMed ID: 34028988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis.
    Tangborwornweerakul B; Phutthinart N; Disayabutr S; Katchamart W
    Semin Arthritis Rheum; 2024 Dec; 69():152564. PubMed ID: 39423699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.